29th Mar 2018 7:00 am |
RNS |
Total Voting Rights |
28th Mar 2018 7:00 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
26th Mar 2018 7:00 am |
RNS |
Annual Report & Notice of Annual General Meeting |
21st Mar 2018 9:25 am |
RNS |
Director's Share Dealing |
20th Mar 2018 9:15 am |
RNS |
Grant of Share Options under Share Option Scheme |
19th Mar 2018 7:10 am |
RNS |
Director's Share Dealing |
12th Mar 2018 11:22 am |
RNS |
Publication of Form 20-F |
12th Mar 2018 7:02 am |
RNS |
Final Results and Key Clinical Programs Update |
6th Mar 2018 7:00 am |
RNS |
Phase Ib/II Trial of Epitinib in Glioblastoma |
13th Feb 2018 7:01 am |
RNS |
Enrolment completed Ph III FALUCA Fruquintinib |
5th Feb 2018 7:00 am |
RNS |
Chi-Med to Announce 2017 Final Results |
29th Dec 2017 7:00 am |
RNS |
Block listing Interim Review |
29th Dec 2017 7:00 am |
RNS |
Total Voting Rights |
15th Dec 2017 7:00 am |
RNS |
Chi-Med Initiates Fruquintinib US Clinical Trials |
1st Nov 2017 9:45 am |
RNS |
Notification of Major Holdings |
1st Nov 2017 9:45 am |
RNS |
NOTIFICATION OF MAJOR HOLDINGS |
31st Oct 2017 7:00 am |
RNS |
FRUTIGA, a Phase III trial of Fruquintinib |
30th Oct 2017 3:30 pm |
RNS |
Closing of U.S. Public Offering of ADSs |
27th Oct 2017 12:10 pm |
RNS |
Chi-Med Announces Over-allotment Option |
26th Oct 2017 7:00 am |
RNS |
Chi-Med Announces Pricing Raising US$262 million |
25th Oct 2017 7:00 am |
RNS |
Chi-Med Announces Proposed Offering of ADSs |
19th Oct 2017 9:20 am |
RNS |
Notification of Major Interest in Shares |
17th Oct 2017 7:00 am |
RNS |
Savolitinib Shows Encouraging Clinical Activity |
16th Oct 2017 7:00 am |
RNS |
Chi-Med Reports Preliminary Phase II data |
12th Oct 2017 7:30 am |
RNS |
Appointment of Director |
29th Sep 2017 7:04 am |
RNS |
Savolitinib and Fruquintinib presentations at WCLC |
29th Sep 2017 7:00 am |
RNS |
Oral Presentations at CSCO Annual Meeting |
29th Sep 2017 7:00 am |
RNS |
Total Voting Rights |
31st Aug 2017 10:15 am |
RNS |
Director's Share Dealing |
29th Aug 2017 7:00 am |
RNS |
Start of HMPL 689 Phase I Trial in China |
22nd Aug 2017 9:00 am |
RNS |
Director's Share Dealing |
18th Aug 2017 10:50 am |
RNS |
Directors' Share Dealing |
15th Aug 2017 10:30 am |
RNS |
Directors' Share Dealing |
10th Aug 2017 9:35 am |
RNS |
Director's Share Dealing |
7th Aug 2017 9:45 am |
RNS |
Directors' Share Dealing |
31st Jul 2017 7:00 am |
RNS |
Chi-Med Reports 2017 Interim Results |
30th Jun 2017 7:00 am |
RNS |
Total Voting Rights |
29th Jun 2017 7:00 am |
RNS |
Chi-Med to Announce 2017 HY Financial Results |
29th Jun 2017 7:00 am |
RNS |
Blocklisting Six Monthly Return |
29th Jun 2017 7:00 am |
RNS |
Start of Savolitinib Global PRCC Phase III Trial |